Sonpiretigene Isteparvovec - Nanoscope Therapeutics
Alternative Names: MCO-010; vMCO 1; vMCO-010Latest Information Update: 02 Apr 2024
At a glance
- Originator Nanoscope Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Eye protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Retinitis pigmentosa; Stargardt disease
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 26 Mar 2024 Nanoscope Therapeutics announces intention to submit BLA to the US FDA for Retinitis pigmentosa in the US in the second half of 2024
- 26 Mar 2024 Efficacy and adverse events data from a phase IIb RESTORE trial in Retinitis pigmentosa released by Nanoscope Therapeutics
- 18 Jan 2024 Nanoscope Therapeutics completes a phase IIb RESTORE trial in Retinitis pigmentosa in USA, Puerto Rico (Intravitreous) (NCT04945772)